Peloton Therapeutics Adds $22.2M

Dallas-based cancer therapy developer Peloton Therapeutics said this week that it has raised $22.2M in its Series D funding, bringing the round to $74.6M. Source of the additional funding was not announced. Peloton Therapeutics had earlier announced $52.4M in a close on its Series D funding. The company is developing small molecule cancer therapy. Pelton is led by CEO John A. Josey, Ph.D. The earlier Series D tranche came from Foresite Capital Management, Remeditex LLC, The Column Group, Tichenor Ventures LLC, Topspin Fund LP, and Nextech Invest Ltd. More information »